+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Angiotensin Converting Enzyme (ACE) Inhibitors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 120 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5707276
This report titled angiotensin converting enzyme (ACE) inhibitors market studies various drug type, application type and geographical scenario. According to Cleveland Clinic, an ACE inhibitor is a type of vasodilator that dilates the blood vessels to improve the amount of blood the heart pumps in patients suffering from high blood pressure. An ACE inhibitor also increases blood flow, which will help decrease the amount of work the heart has to do and may also decrease your blood pressure. The renin-angiotensin-aldos-terone system (RAAS) plays a key physiologic role in the regulation of blood pressure in the human body. In RAAS, ACE plays an important role in the production of angiotensin II where it facilitates the conversion of the biologically inactive angiotensin I to angiotensin II. Angiotensin II increases blood pressure by its action as a potent vasoconstrictor and stimulates the production of aldosterone, which promotes sodium and water retention in the body. Therefore, a substance that inhibits ACE will decrease the production of angiotensin II and reduce blood pressure. According to World Health Organization (WHO), high blood pressure is one of the most important causes of premature death worldwide killing nearly 9.4 million people every year globally, and the problem is growing. The WHO data further suggested that the prevalence of raised blood pressure was highest in the African Region (46%) and lowest in the Region of the Americas (35%). In the South-East Asia Region, 36% of adults have hypertension. Thus, rising prevalence of hypertension and diabetes, and high public awareness related with early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitors market.

The major key players profiled in the ACE inhibitors market are on the basis of various characteristics such as business description, financial health and budget allocation, product portfolio, and news coverage. The key players profiled in this report are Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Jhonson and Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Angiotensin Converting Enzyme (ACE) Inhibitors market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Angiotensin Converting Enzyme (ACE) Inhibitors market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Type

  • Benazepri
  • Captopril
  • Enalapril
  • Fosinopril
  • Lisinopril
  • Moexipril
  • Perindopril
  • Quinapril
  • Ramipril
  • Trandolapril
  • Combination ACE Inhibitors

Application

  • Hypertension
  • Coronary Artery Diseases
  • Heart Failure
  • Myocardial Infarction
  • Diabetes
  • Chronic Kidney Disorders
  • Others (Scleroderma, Migraine and others)

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Angiotensin Converting Enzyme (ACE) Inhibitors market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Angiotensin Converting Enzyme (ACE) Inhibitors market?
  • Which is the largest regional market for Angiotensin Converting Enzyme (ACE) Inhibitors market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Angiotensin Converting Enzyme (ACE) Inhibitors market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Angiotensin Converting Enzyme (ACE) Inhibitors market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Angiotensin Converting Enzyme (ACE) Inhibitors Market
2.2. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drug Type, 2021 (US$ Million)
2.3. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Application, 2021 (US$ Million)
2.4. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Geography, 2021 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2021
3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: Competitive Analysis
3.1. Market Positioning of Key Angiotensin Converting Enzyme (ACE) Inhibitors Market Vendors
3.2. Strategies Adopted by Angiotensin Converting Enzyme (ACE) Inhibitors Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Angiotensin Converting Enzyme (ACE) Inhibitors Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Benazepri
5.3.2. Captopril
5.3.3. Enalapril
5.3.4. Fosinopril
5.3.5. Lisinopril
5.3.6. Moexipril
5.3.7. Perindopril
5.3.8. Quinapril
5.3.9. Ramipril
5.3.10. Trandolapril
5.3.11. Combination ACE Inhibitors
6. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Hypertension
6.3.2. Coronary Artery Diseases
6.3.3. Heart Failure
6.3.4. Myocardial Infarction
6.3.5. Diabetes
6.3.6. Chronic Kidney Disorders
6.3.7. Others (Scleroderma, Migraine and others)
7. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
7.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
7.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2020-2030, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
7.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
7.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
7.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
8. UK and European Union Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
8.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
8.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2020-2030, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.4.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
8.4.1.5. France
8.4.1.5.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.5.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
8.4.1.6.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
9. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
9.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
9.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2020-2030, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
9.4.1.3. India
9.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.4.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.5.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
9.4.1.6.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
10. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
10.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
10.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2020-2030, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
10.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
10.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
10.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
11. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
11.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
11.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2020-2030, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
11.4.1.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
11.4.1.2.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
11.4.1.3.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
12. Company Profile
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Pfizer, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Merck & Co.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Astra Zeneca plc
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Jhonson and Johnson Limited
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Eli Lilly and Company
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Sanofi SA
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Bristol-Myers Squibb Company
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Bayer AG
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. GlaxoSmithKline plc
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Teva Pharmaceutical Industries Ltd.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
List of Figures
Figure 1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Quality Assurance
Figure 5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drug Type, 2021
Figure 6 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Application, 2021
Figure 7 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Geography, 2021
Figure 8 Market Geographical Opportunity Matrix - Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2021
Figure 9 Market Positioning of Key Angiotensin Converting Enzyme (ACE) Inhibitors Market Players, 2021
Figure 10 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 11 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drug Type, 2021 Vs 2030, %
Figure 12 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Application, 2021 Vs 2030, %
Figure 13 U.S. Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 14 Canada Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 15 Rest of North America Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 16 UK Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 17 Germany Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 18 Spain Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 19 Italy Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 20 France Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 21 Rest of Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 22 China Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 23 Japan Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 24 India Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 25 Australia Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 26 South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 27 Rest of Asia Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 28 Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 29 Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 30 Rest of Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 31 GCC Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 32 Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
Figure 33 Rest of Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 3 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 4 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 5 U.S. Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 6 U.S. Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 7 Canada Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 8 Canada Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 9 Rest of North America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 10 Rest of North America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 11 UK and European Union Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 12 UK and European Union Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 13 UK Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 14 UK Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 15 Germany Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 16 Germany Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 17 Spain Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 18 Spain Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 19 Italy Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 20 Italy Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 21 France Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 22 France Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 23 Rest of Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 24 Rest of Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 25 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 26 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 27 China Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 28 China Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 29 Japan Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 30 Japan Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 31 India Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 32 India Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 33 Australia Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 34 Australia Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 35 South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 36 South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 37 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 38 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 39 Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 40 Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 41 Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 42 Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 43 Rest of Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 44 Rest of Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 45 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 46 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 47 GCC Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 48 GCC Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 49 Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 50 Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
Table 51 Rest of Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
Table 52 Rest of Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)

Companies Mentioned

  • Abbott Laboratories
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co.
  • Astra Zeneca plc
  • Jhonson and Johnson Limited
  • Eli Lilly and Company
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • Bayer AG
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.